vs
Side-by-side financial comparison of MIND CTI LTD (MNDO) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $4.9M, roughly 1.9× MIND CTI LTD). MIND CTI LTD runs the higher net margin — 19.4% vs -60.3%, a 79.8% gap on every dollar of revenue. MIND CTI LTD produced more free cash flow last quarter ($4.0M vs $1.6M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -45.1%).
MIND CTI Ltd. is a global provider of billing and customer care solutions and messaging services for voice, data, video and content services. Headquartered in Yokneam, Israel; the company also has offices in the United States of America, Iaşi in Romania and in Germany.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MNDO vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9M | $9.1M |
| Net Profit | $950.0K | $-5.5M |
| Gross Margin | 55.4% | 49.4% |
| Operating Margin | 16.5% | -51.1% |
| Net Margin | 19.4% | -60.3% |
| Revenue YoY | — | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $0.05 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9M | $9.1M | ||
| Q3 25 | $16.2M | $17.9M | ||
| Q2 25 | $11.0M | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | $5.2M | $18.2M | ||
| Q3 24 | $16.0M | $18.0M | ||
| Q2 24 | $10.7M | $13.5M | ||
| Q4 23 | $5.6M | $10.5M |
| Q4 25 | $950.0K | $-5.5M | ||
| Q3 25 | $3.4M | $2.4M | ||
| Q2 25 | $2.5M | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | $1.2M | $6.5M | ||
| Q3 24 | $3.7M | $3.2M | ||
| Q2 24 | $2.5M | $-2.2M | ||
| Q4 23 | $1.4M | $-6.0M |
| Q4 25 | 55.4% | 49.4% | ||
| Q3 25 | 48.3% | 53.4% | ||
| Q2 25 | 50.6% | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | 55.6% | 78.7% | ||
| Q3 24 | 50.6% | 53.4% | ||
| Q2 24 | 50.4% | 29.8% | ||
| Q4 23 | 49.5% | 15.5% |
| Q4 25 | 16.5% | -51.1% | ||
| Q3 25 | 18.8% | 11.9% | ||
| Q2 25 | 21.0% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | 25.4% | 39.6% | ||
| Q3 24 | 22.5% | 22.2% | ||
| Q2 24 | 22.2% | -18.0% | ||
| Q4 23 | 20.6% | -53.5% |
| Q4 25 | 19.4% | -60.3% | ||
| Q3 25 | 20.9% | 13.2% | ||
| Q2 25 | 22.3% | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | 23.8% | 35.6% | ||
| Q3 24 | 23.3% | 18.0% | ||
| Q2 24 | 23.1% | -16.4% | ||
| Q4 23 | 25.6% | -57.6% |
| Q4 25 | $0.05 | $-0.06 | ||
| Q3 25 | $0.16 | $0.03 | ||
| Q2 25 | $0.12 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | $0.06 | $0.10 | ||
| Q3 24 | $0.18 | $0.03 | ||
| Q2 24 | $0.12 | $-0.03 | ||
| Q4 23 | $0.06 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.3M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.0M | $48.2M |
| Total Assets | $30.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.3M | $14.7M | ||
| Q3 25 | $4.5M | $13.6M | ||
| Q2 25 | $4.5M | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | $4.6M | $19.8M | ||
| Q3 24 | $3.0M | $27.4M | ||
| Q2 24 | $3.0M | $23.4M | ||
| Q4 23 | $16.4M | $23.6M |
| Q4 25 | $23.0M | $48.2M | ||
| Q3 25 | $24.3M | $52.9M | ||
| Q2 25 | $24.3M | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | $24.3M | $43.2M | ||
| Q3 24 | $24.5M | $32.4M | ||
| Q2 24 | $24.5M | $28.6M | ||
| Q4 23 | $24.5M | $33.6M |
| Q4 25 | $30.2M | $82.3M | ||
| Q3 25 | $30.7M | $82.3M | ||
| Q2 25 | $30.7M | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | $30.7M | $73.4M | ||
| Q3 24 | $31.6M | $61.6M | ||
| Q2 24 | $31.6M | $91.5M | ||
| Q4 23 | $31.6M | $84.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $2.0M |
| Free Cash FlowOCF − Capex | $4.0M | $1.6M |
| FCF MarginFCF / Revenue | 81.0% | 17.8% |
| Capex IntensityCapex / Revenue | 0.6% | 4.4% |
| Cash ConversionOCF / Net Profit | 4.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.7M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $2.0M | ||
| Q3 25 | $3.8M | $-3.7M | ||
| Q2 25 | $2.9M | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | $4.1M | $4.0M | ||
| Q3 24 | $3.4M | $4.1M | ||
| Q2 24 | $2.4M | $-3.6M | ||
| Q4 23 | $4.1M | $3.6M |
| Q4 25 | $4.0M | $1.6M | ||
| Q3 25 | $3.8M | $-4.2M | ||
| Q2 25 | $2.9M | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $4.1M | $3.6M | ||
| Q3 24 | $3.3M | $4.0M | ||
| Q2 24 | $2.4M | $-3.8M | ||
| Q4 23 | $4.0M | $3.3M |
| Q4 25 | 81.0% | 17.8% | ||
| Q3 25 | 23.4% | -23.7% | ||
| Q2 25 | 25.8% | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | 78.9% | 19.6% | ||
| Q3 24 | 20.8% | 22.4% | ||
| Q2 24 | 22.1% | -28.1% | ||
| Q4 23 | 72.0% | 31.9% |
| Q4 25 | 0.6% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.4% | 1.3% | ||
| Q4 23 | 1.1% | 2.4% |
| Q4 25 | 4.20× | — | ||
| Q3 25 | 1.12× | -1.58× | ||
| Q2 25 | 1.16× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.32× | 0.61× | ||
| Q3 24 | 0.91× | 1.27× | ||
| Q2 24 | 0.97× | — | ||
| Q4 23 | 2.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MNDO
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
